ArticleBiomaterials research2026
A Hybrid Mesenchymal-Stem-Cell-Derived Decellularized Matrix Scaffold Supports Bone Repair and Vascular Perfusion in Steroid-Associated Osteonecrosis.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-associated osteonecrosis (SAON) is characterized by glucocorticoid-associated vascular compromise, impaired bone repair, and a dysregulated inflammatory microenvironment. Although core decompression (CD) remains the main joint-preserving procedure, its efficacy is often limited by the hostile local niche. Here, we engineered a hybrid CDM@Fibrin/poly(ε-caprolactone) (PCL) scaffold by incorporating human umbilical cord mesenchymal-stem-cell-derived decellularized matrix (CDM) into a 3D-printed PCL framework. Proteomic profiling showed enrichment of extracellular-matrix-associated proteins linked to focal adhesion, extracellular matrix-receptor interaction, and phosphatidylinositol 3-kinase-Akt-related signaling. In vitro, solubilized CDM was biocompatible and modulated macrophage behavior in a context-dependent manner; under basal conditions, its effects on canonical polarization markers were modest, whereas under inflammatory challenge it attenuated lipopolysaccharide-induced M1-like activation and partially restored pro-healing features. In a rat femoral condyle defect model, CDM@Fibrin/PCL enhanced bone formation and was associated with lower CD86 and relatively higher CD206 signals than Fibrin/PCL controls. In a preclinical SAON model, scaffold-augmented CD markedly improved new bone formation and perfused vascular volume relative to CD alone. Exploratory transcriptomic analysis identified pathway-level associations related to immune regulation, extracellular matrix remodeling, and reparative signaling. Collectively, these findings suggest that mesenchymal-stem-cell-derived CDM functions as a bioactive matrix component that helps rebalance the local inflammatory niche and supports bone repair with improved vascularization-related outcomes in SAON.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.